Epstein Secrets

evices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs

to diagnose genetic diseases (i.e. cystic fibrosis, MLPA tests, D=NSR for NIPD of trisomy), and identify diseases using DNA microarrays a=d targeted Next-Gen sequencing. Earlier this year, I receiv=d the IFCC Award for Significant Contributions in Molecular Diagnostic=. I have been collaborating with Dr.

ricated devices that w=ll allow for electronic detection, obviating the need for expens=ve hardware used in most fluorescent detection schemes (i.e. Taqman a=says). As such, we are poised to combine these technologie= for rapidly identifying and providing quantitative viral load fo= all the VHF, Variol

to diagnose genetic diseases (i.e. cystic fibrosis, MLPA tests, =ANSR for NIPD of trisomy), and identify diseases using DNA microarray= and targeted Next-Gen sequencing. Earlier this year, I re=eived the IFCC Award for Significant Contributions in Molecular Diagn=stics. I have been collaborating with Dr.

devices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs

o diagnose genetic diseases (i.e. cystic fibrosis, MLPA tests, C0=NSR for NIPD of trisomy), and identify diseases using DNA microarrays a=d targeted Next-Gen sequencing. Earlier this year, I receiv=d the IFCC Award for Significant Contributions in Molecular Diagnostic=. I have been collaborating with Dr.